Australia, Oct. 28 -- Bristol-Myers Squibb Co., owns the trademark (2573783) for 'FYMILSI' till Aug. 5, 2035.
Status: registered:
Registered/protected
Classes: 5 [Pharmaceutical preparations for the treatment and prevention of oncological, hematological, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric, and immune system related diseases and disorders; stem cells for medical purposes; diagnostic radiopharmaceutical preparations; diagnostic preparations for medical purposes; radiopharmaceutical preparations for the treatment of cancer and immune system related diseases and disorders.] and 5 [All items in this class are claimed in the convention application.]
Type of Mark: Word
Date of Acceptance: Aug. 19
Registration Advertised: Oct. 27
For further details contact Spruson & Ferguson.
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2573783.
Disclaimer: Curated by HT Syndication.
